Volume : 08, Issue : 05, May – 2021

Title:

6.METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF SPARFLOXACIN IN BULK AND TABLET DOSAGE FORM BY UV-SPECTROSCOPY

Authors :

K. Priyanka*, Aliveni Patlolla, Deepthi Visakh

Abstract :

Pharmaceutical analysis simply means analysis of pharmaceuticals. Webster’ dictionary defines a pharmaceutical is a medical drug. A more appropriate term for a pharmaceutical is active pharmaceutical ingredient (API) or active ingredient to distinguish it from a formulated product or drug product is prepared by formulating a drug substance with inert ingredient (excipient) to prepare a drug product that is suitable for administration to patients. Research and development (R&D) play a very comprehensive role in new drug development and follow up activities to ensure that a new drug product meets the established standards is stable and continue to approved by regulatory authorities, assuring that all batches of drug product are made to the specific standards utilization of approved ingredients and production method becomes the responsibility of pharmaceutical analysts in the quality control (QC) or quality assurance department. The methods are generally developed in an analytical R&D department and transferred to QC or other departments as needed. At times they are transferred to other divisions.
Key Words: API, quality control, Research and development (R&D), excipient

Cite This Article:

Please cite this article in press K. Priyanka et al., Method Development And Validation For The Estimation Of Sparfloxacin In Bulk And Tablet Dosage Form By UV-Spectroscopy.., Indo Am. J. P. Sci, 2021; 08(05).

Number of Downloads : 10

References:

1. Borner, K., Borner, E. & Lode, H. (1992). Determination of sparfloxacin in serum and urine by high-performance liquid chromatography. Journal of Chromatography and Biomedical Applications.
2. Dabernat, H., Delmas, C. Seguy, M. & Lareng, M. B. (1991). Comparative in vitro activity of sparfloxacin against Haemophilus influenzae and Branhamella calarrhalis. European Journal of Clinical Microbiology and Infectious Diseases Special Issue.
3. El-Sayed, Y. M. (1995). A simple high-performance liquid chromatographic assay for sparfloxacin in human plasma. Analytical Letters.
4. Genevois. E., Lelouer, V., Vercken, J.-B. & Caillon, R. (1996). Study design, methodology and statistical analyses in the clinical development of sparfloxacin. Journal of Antimicrobial Chemotherapy, Suppl. A.
5. Harrison, B. D. W., Farr, B. M., Connolly, C. K., MacFarlane, J. T., Selkon, J. B. & Bartlett, C. L. R. (1987). The hospital management of community-acquired pneumonia. Recommendations of the British Thoracic Society. Journal of the Roval College of Physicians of London.
6. Honeybourne, D., Greaves. I., Baldwin, D. R., Andrews. J. M., Harris, M. & Wise, R. (1994). The concentration of sparfloxacin in lung tissues after single and multiple oral doses. International Journal of Antimicrobial Agents.
7. Journal of Optoelectronics and Biomedical Materials Vol. 2, Issue 4, October-December 2010
8. Miyamoto, T., Matsumoto, J. I., Chiba, K., Egawa, H., Shibamori, K., Minamida, A. et al. (1990). Synthesis and structure activity relationships of 5-substituted 6,8 fluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. Journal of Medicinal Chemistry.
9. Miyamoto, T., Matsumoto, J. I., Chiba, K., Egawa, H., Shibamori, K., Minamida, A. et al. (1990). Synthesis and structure activity relationships of 5-substituted 6,8 fluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. Journal of Medicinal Chemistry.
10. Nilsen, O. G. (1987). Comparative pharmacokinetics of macrolides. Journal of Antimicrobial Chemotherapy, Suppl. B.Perrone, C., Gikas, A., Truffot-Pernot, C., Grosset, J., Vilde, J. L. & Pocidalo, J. J. (1991). Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrobial Agents and Chemotherapy.
11. Rastogi, N. & Goh, K. S. (1989). In vitro activity of the new difluorinated sparfloxacin against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrobial Agents and Chemotherapy.
12. Rubinstein, E. (1996). Safety profile of sparfloxacin in the treatment of respiratory tract infections. Journal of Antimicrobial Chemotherapy, Suppl. A.
13. Shimada, J., Nogita, T. & Ishibashi, Y. (1993). Clinical pharmacokinetics of sparfloxacin. Clinical Pharmacokinetics.
14. Srikar A et al /J. Pharm. Sci. & Res. Vol.1(2),
15. The British Journal for Antimicrobial Chemotherapy Validation Of Analytical Procedures: Text And Methodology_ Q2(R1).